Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Nov 17, 2025
Date Accepted: Jan 20, 2026
Date Submitted to PubMed: Jan 27, 2026

The final, peer-reviewed published version of this preprint can be found here:

Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial

Koseki T, Fujigaki H, Kikuchi K, Oya Y, Kato H, Mizuno T, Tsuboi N, Kawada K, Goto Y, Hashimoto N, Imaizumi K, Kada A, Yabuuchi H, Saito K, Kondo M, Saya H

Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial

JMIR Res Protoc 2026;15:e87907

DOI: 10.2196/87907

PMID: 41592613

PMCID: 12946776

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Per the author's request this version is not available.